FACTORS ASSOCIATED WITH DEVELOPMENT OF MENTAL ILLNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A POPULATION-BASED STUDY

被引：0

作者：

Chen, H. H. ^{[1
,2
]}

Chao, W. C. ^{[1
,3
]}

机构：

[1] Natl Chung Hsing Univ, Dept Postbaccalaureate Med, Taichung, Taiwan

[2] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan

[3] Taichung Vet Gen Hosp, Dept Crit Care Med, Taichung, Taiwan

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Targeted synthetic drugs; bDMARD; Mental health;

D O I：

10.1136/annrheumdis-2023-eular.1176

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0289

引用

页码：1326 / 1326

页数：1

共 50 条

[31] EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Smolen, Josef S.
Landewe, Robert B. M.
Bijlsma, Johannes W. J.
Burmester, Gerd R.
Dougados, Maxime
Kerschbaumer, Andreas
McInnes, Iain B.
Sepriano, Alexandre
van Vollenhoven, Ronald F.
de Wit, Maarten
Aletaha, Daniel
Aringer, Martin
Askling, John
Balsa, Alejandro
Boers, Maarten
den Broeder, Alfons A.
Buch, Maya H.
Buttgereit, Frank
Caporali, Roberto
Cardiel, Mario Humberto
De Cock, Diederik
Codreanu, Catalin
Cutolo, Maurizio
Edwards, Christopher John
van Eijk-Hustings, Yvonne
Emery, Paul
Finckh, Axel
Gossec, Laure
Gottenberg, Jacques-Eric
Hetland, Merete Lund
Huizinga, Tom W. J.
Koloumas, Marios
Li, Zhanguo
Mariette, Xavier
Mueller-Ladner, Ulf
Mysler, Eduardo F.
da Silva, Jose A. P.
Poor, Gyula
Pope, Janet E.
Rubbert-Roth, Andrea
Ruyssen-Witrand, Adeline
Saag, Kenneth G.
Strangfeld, Anja
Takeuchi, Tsutomu
Voshaar, Marieke
Westhovens, Rene
van der Heijde, Desiree
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) : 685 - 699
[32] EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Smolen, Josef S.
Landewe, Robert
Bijlsma, Johannes
Burmester, Gerd
Chatzidionysiou, Katerina
Dougados, Maxime
Nam, Jackie
Ramiro, Sofia
Voshaar, Marieke
van Vollenhoven, Ronald
Aletaha, Daniel
Aringer, Martin
Boers, Maarten
Buckley, Chris D.
Buttgereit, Frank
Bykerk, Vivian
Cardiel, Mario
Combe, Bernard
Cutolo, Maurizio
van Eijk-Hustings, Yvonne
Emery, Paul
Finckh, Axel
Gabay, Cem
Gomez-Reino, Juan
Gossec, Laure
Gottenberg, Jacques-Eric
Hazes, Johanna M. W.
Huizinga, Tom
Jani, Meghna
Karateev, Dmitry
Kouloumas, Marios
Kvien, Tore
Li, Zhanguo
Mariette, Xavier
McInnes, Iain
Mysler, Eduardo
Nash, Peter
Pavelka, Karel
Poor, Gyula
Richez, Christophe
van Riel, Piet
Rubbert-Roth, Andrea
Saag, Kenneth
da Silva, Jose
Stamm, Tanja
Takeuchi, Tsutomu
Westhovens, Rene
de Wit, Maarten
van der Heijde, Desiree
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 960 - 977
[33] EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Smolen, Josef S.
Landewe, Robert
Breedveld, Ferdinand C.
Buch, Maya
Burmester, Gerd
Dougados, Maxime
Emery, Paul
Gaujoux-Viala, Cecile
Gossec, Laure
Nam, Jackie
Ramiro, Sofia
Winthrop, Kevin
de Wit, Maarten
Aletaha, Daniel
Betteridge, Neil
Bijlsma, Johannes W. J.
Boers, Maarten
Buttgereit, Frank
Combe, Bernard
Cutolo, Maurizio
Damjanov, Nemanja
Hazes, Johanna M. W.
Kouloumas, Marios
Kvien, Tore K.
Mariette, Xavier
Pavelka, Karel
van Riel, Piet L. C. M.
Rubbert-Roth, Andrea
Scholte-Voshaar, Marieke
Scott, David L.
Sokka-Isler, Tuulikki
Wong, John B.
van der Heijde, Desiree
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (03) : 492 - 509
[34] Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control
Lillegraven, Siri
Sundlisaeter, Nina Paulshus
Aga, Anna-Birgitte
Sexton, Joseph
Solomon, Daniel H.
van der Heijde, Desiree
Haavardsholm, Espen A.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (12): : 1024 - 1026
[35] Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010
Ichinose, Kunihiro
Shimizu, Toshimasa
Umeda, Masataka
Fukui, Shoichi
Nishino, Ayako
Koga, Tomohiro
Kawashiri, Shin-ya
Iwamoto, Naoki
Tamai, Mami
Nakamura, Hideki
Sato, Shuntaro
Origuchi, Tomoki
Kawakami, Atsushi
JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
[36] Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis
Yamanaka, Hisashi
Kishimoto, Mitsumasa
Nishijima, Nobuo
Yamashita, Katsuhisa
Matsushima, Junnosuke
O'Brien, Jacqueline
Blachley, Taylor
Eliot, Melissa
Margolin, Zachary
Dave, Swapna S.
Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2023, 34 (01) : 27 - 36
[37] Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Inose, Ryo
Hashimoto, Natsue
Hosomi, Kouichi
Yokoyama, Satoshi
Takada, Mitsutaka
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (03) : 131 - 138
[38] PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Schlager, Lukas
Loiskandl, Michaela
Aletaha, Daniel
Radner, Helga
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1152 - 1153
[39] Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: A population-based incidence cohort of patients with rheumatoid arthritis
Maradit-Kremers, H
Nicola, PJ
Crowson, CS
O'Fallon, WM
Gabriel, SE
JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 248 - 255
[40] Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland
Burkard, Theresa
Vallejo-Yague, Enriqueta
Huegle, Thomas
Finckh, Axel
Burden, Andrea Michelle
BMJ OPEN, 2022, 12 (03):

← 1 2 3 4 5 →